Wörwag Pharma invests in further growth

Reading time 2 minutes

Böblingen, March 16, 2023 – The Böblingen-based pharmaceutical and family-owned company Wörwag Pharma closed the 2022 financial year with an increase in sales of almost eight percent compared to the previous year. Further growth is planned for 2023 in conjunction with a wide range of investments.


Wörwag Pharma is managed by Dr. Lucia Cinque (Chief Innovation Officer), Gerhard Mayer (Chief Financial Offer) and Jochen Schlindwein (Chief Executive Officer), who had invited to the press conference. Looking back at 2022 and looking ahead to 2023, it became clear that the company is aiming for significant growth, which this year will primarily involve investments in marketing, employees and innovations.  

In 2022, Wörwag Pharma reported sales of over 291 million euros and solid growth in almost all countries. The number of employees worldwide increased from 1,200 in the previous year to 1,400. Further product transfers to the company's own production site Wörwag Pharma Operations (WPO) in Lodz, Poland, and an expansion of innovation capacities are planned for 2023. Sales activities will be further expanded in Colombia and the United Arab Emirates, and the same applies to the sales force in selected countries, primarily in Asia and Central Asia. Also domestic pharmacy sales are to be strengthened further.

The next new addition to the company's own geographical map will be Switzerland in the coming months. In Austria, the company entered the market in January of this year with B12 Ankermann®: The product is the highest-dosed oral vitamin B12 drug in Austria. Also in January, the German magazine Öko-Test took a close look at various vitamin B12 products: Wörwag Pharma's B12 Ankermann® products were rated "good", putting them well ahead of the field: only nine of the 29 products tested received a "good" or "very good" rating. All the others are not recommendable according to the Öko-Test verdict.

Thanks to the company's own WPO production facility, the proportion of products manufactured in-house is rising continuously – the first commercial deliveries from WPO to the group of companies were made in 2022. Here, too, those responsible are placing a great deal of emphasis on investment: With the modernization of existing packaging lines and the implementation of modern machines, as well as the development of processes, know-how and infrastructure, the company sees itself on a good path.

One of Wörwag Pharma’s most successful brands: B12 Ankermann®